← The Wire
RXRXNasdaq
RECURSION PHARMACEUTICALS, INC.
Biological Products, (No Diagnostic Substances) · DE · CIK 1601830
Recursion decodes biology using an AI platform to discover and develop new medicines faster and better
red 8-K · 90d
$1.67B
Market cap
$3.69
Last close
+4.8%
1D
+16.0%
5D
22.9M
Volume
Price · last 39 sessions+4.8%
May 4L $2.85 · H $3.80Jun 29
148
Total filings
Jun 18, 2026
Last filing
12/31
Fiscal year end
8-KShareholder VoteJun 18, 202610-Q10-QMay 6, 20268-KResults of Operations · Reg FD DisclosureMay 6, 2026DEFA14ADEFA14AApr 30, 2026DEF 14ADEF 14AApr 30, 20268-KExecutive Change · Reg FD DisclosureApr 30, 20268-KExecutive Change · Reg FD DisclosureMar 25, 2026424B5424B5Feb 25, 202610-K10-KFeb 25, 20268-KResults of Operations · Reg FD DisclosureFeb 25, 20268-KReg FD DisclosureJan 12, 2026SC 13D/ASC 13D/ADec 23, 20258-KCompany UpdateDec 8, 20258-KCompany UpdateNov 26, 202510-Q10-QNov 5, 20258-KExecutive Change · Results of OperationsNov 5, 20258-KCompany UpdateOct 29, 20258-K/AEquity Issuance · Company UpdateAug 29, 202510-Q10-QAug 5, 20258-KResults of Operations · Reg FD DisclosureAug 5, 20258-KEquity Issuance · Reg FD DisclosureJul 8, 20258-KShareholder VoteJun 18, 20258-KExit / Disposal Costs · Reg FD DisclosureJun 10, 20258-KCompany UpdateMay 9, 202510-Q10-QMay 5, 20258-KResults of Operations · Reg FD DisclosureMay 5, 2025DEFA14ADEFA14AApr 28, 2025DEF 14ADEF 14AApr 28, 20258-KExecutive Change · Reg FD DisclosureMar 18, 2025424B5424B5Feb 28, 202510-K10-KFeb 28, 20258-KResults of Operations · Reg FD DisclosureFeb 28, 20258-KReg FD DisclosureJan 13, 20258-KCompany UpdateDec 17, 20248-KExecutive ChangeDec 3, 20248-K/ACompany UpdateNov 27, 20248-K/AEquity IssuanceNov 26, 20248-KExecutive Change · Acquisition / DispositionNov 20, 20248-KShareholder VoteNov 13, 20248-KCompany UpdateNov 13, 202410-Q10-QNov 6, 20248-KResults of Operations · Reg FD DisclosureNov 6, 2024DEFA14ADEFA14ANov 6, 20248-KMaterial Agreement · Company UpdateNov 6, 2024DEFA14ADEFA14AOct 30, 20248-KReg FD DisclosureOct 2, 2024DEFA14ADEFA14ASep 19, 2024DEFA14ADEFA14ASep 4, 2024DEFA14ADEFA14ASep 3, 20248-KReg FD Disclosure · Company UpdateSep 3, 2024DEFA14ADEFA14AAug 28, 20248-KCompany UpdateAug 28, 2024DEFA14ADEFA14AAug 9, 2024DEFA14ADEFA14AAug 8, 2024DEFA14ADEFA14AAug 8, 202410-Q10-QAug 8, 20248-KExecutive Change · Material AgreementAug 8, 20248-KCompany UpdateAug 6, 2024SC 13GSC 13GJul 8, 2024424B5424B5Jun 27, 20248-KCompany UpdateJun 27, 2024424B5424B5Jun 26, 20248-KReg FD DisclosureJun 24, 20248-KShareholder VoteJun 7, 2024DEFA14ADEFA14AMay 24, 20248-KAuditor Change · Executive ChangeMay 24, 202410-Q10-QMay 9, 20248-KAuditor Change · Results of OperationsMay 9, 2024DEFA14ADEFA14AApr 23, 2024DEF 14ADEF 14AApr 23, 20248-KExecutive Change · Reg FD DisclosureApr 16, 202410-K10-KFeb 29, 20248-KResults of Operations · Reg FD DisclosureFeb 27, 2024SC 13GSC 13GFeb 9, 20248-KExecutive ChangeFeb 7, 20248-KBylaw AmendmentJan 31, 2024SC 13GSC 13GJan 29, 2024SC 13GSC 13GJan 24, 20248-KReg FD DisclosureJan 8, 20248-KReg FD DisclosureDec 20, 2023
Insider Activity
In the 90 days to Mar 23, 2026: 4 sold $3.5M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 23, 2026 | Gibson ChristopherDirector | Sell | 40,000 | $3.25 | $130K |
| Mar 17, 2026 | Taylor Ben RChief Financial Officer | Sell | 7,956 | $3.39 | $27K |
| Mar 9, 2026 | Khan NajatCEO and President | Sell | 28,298 | $3.35 | $95K |
| Mar 3, 2026 | Borgeson BlakeDirector | Sell | 170,000 | $3.46 | $588K |
| Feb 19, 2026 | Gibson ChristopherDirector | Sell | 40,000 | $3.46 | $138K |
| Feb 18, 2026 | Taylor Ben RChief Financial Officer | Sell | 13,426 | $3.08 | $41K |
| Feb 4, 2026 | Gibson ChristopherDirector | Sell | 40,000 | $4.12 | $165K |
| Feb 3, 2026 | Borgeson BlakeDirector | Sell | 220,000 | $4.20 | $924K |
| Jan 20, 2026 | Gibson ChristopherDirector | Sell | 40,000 | $4.47 | $179K |
| Jan 6, 2026 | Borgeson BlakeDirector | Sell | 220,000 | $4.36 | $959K |
| Jan 5, 2026 | Gibson ChristopherDirector | Sell | 40,000 | $4.25 | $170K |
| Dec 29, 2025 | Taylor Ben RChief Financial Officer | Sell | 21,383 | $4.18 | $89K |
| Dec 22, 2025 | Khan NajatChief R&D Commercial Officer | Sell | 124,403 | $4.41 | $549K |
| Dec 19, 2025 | Gibson ChristopherChief Executive Officer | Sell | 40,000 | $4.50 | $180K |
| Dec 4, 2025 | Gibson ChristopherChief Executive Officer | Sell | 40,000 | $4.63 | $185K |
| Dec 2, 2025 | Borgeson BlakeDirector | Sell | 220,000 | $4.37 | $961K |
| Nov 19, 2025 | Gibson ChristopherChief Executive Officer | Sell | 40,000 | $4.16 | $166K |
| Nov 4, 2025 | Gibson ChristopherChief Executive Officer | Sell | 40,000 | $5.21 | $208K |
| Oct 23, 2025 | Gibson ChristopherChief Executive Officer | Sell | 100,000 | $5.70 | $570K |
| Oct 10, 2025 | Gibson ChristopherChief Executive Officer | Sell | 100,000 | $6.04 | $604K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance